Close

H.C. Wainwright Reiterates Buy Rating on Paratek Pharmaceuticals (PRTK), Cites Impressive Preclinical Results in MAC Lung Infections

March 9, 2022 6:10 AM EST Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $27.00 price target on Paratek Pharmaceuticals (NASDAQ: PRTK), following a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login